KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Change in Cash: 2009-2025

Historic Change in Cash for Acadia Pharmaceuticals (ACAD) over the last 16 years, with Sep 2025 value amounting to $4.4 million.

  • Acadia Pharmaceuticals' Change in Cash rose 122.96% to $4.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $103.5 million, marking a year-over-year increase of 72.71%. This contributed to the annual value of $133.9 million for FY2024, which is 81.45% up from last year.
  • As of Q3 2025, Acadia Pharmaceuticals' Change in Cash stood at $4.4 million, which was down 88.10% from $36.6 million recorded in Q2 2025.
  • In the past 5 years, Acadia Pharmaceuticals' Change in Cash ranged from a high of $176.0 million in Q1 2023 and a low of -$180.6 million during Q2 2023.
  • Moreover, its 3-year median value for Change in Cash was $4.4 million (2025), whereas its average is $13.4 million.
  • As far as peak fluctuations go, Acadia Pharmaceuticals' Change in Cash soared by 366.86% in 2022, and later plummeted by 733.35% in 2025.
  • Acadia Pharmaceuticals' Change in Cash (Quarterly) stood at $52.8 million in 2021, then plummeted by 175.76% to -$40.0 million in 2022, then skyrocketed by 326.18% to $90.5 million in 2023, then soared by 81.77% to $164.4 million in 2024, then surged by 122.96% to $4.4 million in 2025.
  • Its Change in Cash was $4.4 million in Q3 2025, compared to $36.6 million in Q2 2025 and -$101.9 million in Q1 2025.